You're not behind — but the decisions you make about potency in the next few months will shape how much work you're doing a year from now.
Early-stage CAR-T programs almost never have this figured out. That's not a failure — it's where the work is.
Why Does This Matter?
Foundational choices made now determine how much needs to be rebuilt later.
The risk isn't where you are today. It's the distance between where you are and what you'll need to show when the stakes get higher. What makes this stage complicated is that these decisions don't feel urgent when you're focused on making the cells work — but they determine how much of your early data will still be usable when you reach regulatory conversations.
What Leading Teams Do Differently?
They start with format selection — choosing a readout that can scale with the program and support a quantitative claim — before optimizing the details. Getting this right early means less rebuilding later.
This allows teams to:
- Establish a potency assay foundation that won't need to be rebuilt as the program advances
- Generate early data that remains usable under regulatory scrutiny
- Plan for cytokine co-readout integration from the beginning rather than retrofitting later
Next Steps: Get potency guidance aligned to your result.
Complete the form below to receive:
- A practical guide to building a potency assay workflow that scales with your program
- Guidance on which format decisions matter most at your stage — and in what order
- Resources aligned to early-stage CAR-T teams building potency assays from the ground up
Solutions that Scale with Your Cell and Gene Therapy Workflow.
From discovery to QC, we deliver reliable, validated tools to accelerate your cell and gene therapy
development pipeline.